NCT00876694View on ClinicalTrials.gov

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Indacaterol 300 µg

Indacaterol 300 µg once daily (od) via SDDPI

DRUG

Salmeterol 50 µg

Salmeterol 50 µg twice daily (bid) via Diskus®

Trial Locations (37)

Unknown

Novartis Investigator Site, Asahikawa

Novartis Investigator Site, Bunkyō City

Novartis Investigator Site, Gifu

Novartis Investigator Site, Hamamatsu

Novartis Investigator Site, Himeji

Novartis Investigator Site, Hiroshima

Novartis Investigator Site, Iwata

Novartis Investigator Site, Kanazawa

Novartis Investigator Site, Kasaoka

Novartis Investigator Site, Kawasaki

Novartis Investigator Site, Kishiwada

Novartis Investigator Site, Kitakyushu

Novartis Investigator Site, Kochi

Novartis Investigator Site, Koga

Novartis Investigator Site, Kurume

Novartis Investigator Site, Kyoto

Novartis Investigator Site, Maebashi

Novartis Investigator Site, Matsusaka

Novartis Investigator Site, Morioka

Novartis Investigator Site, Nagaoka

Novartis Investigator Site, Nagoya

Novartis Investigator Site, Naka-gun

Novartis Investigator Site, Noda

Novartis Investigator Site, Obihiro

Novartis Investigator Site, Sakai

Novartis Investigator site, Sapporo

Novartis Investigator Site, Sendai

Novartis Investigator Site, Setagaya-ku

Novartis Investigator Site, Sumida-ku

Novartis Investigator Site, Tenri

Novartis Investigator Site, Tokyo

Novartis Investigator Site, Ube

Novartis Investigator Site, Wakayama

Novartis Investigator Site, Yabu

Novartis Investigator Site, Yanagawa

Novartis Investigator Site, Yokkaichi

Novartis Investigator Site, Yokohama

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY